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Aim: Pegcantratinib is a mini-PEGylated K252a derivative, under clinical evaluation as 
an anticancer agent acting through inhibition of the tropomyosin receptor kinase. A 
method for quantifying pegcantratinib in skin tumor biopsies of patients was required 
to determine tumor drug penetration. Methods & results: A sensitive and PEGylated 
molecule specific HPLC–MS/MS method coupled with in-source collision-induced 
dissociation was developed. The method exhibited excellent precision (coefficient of 
variation ≤8.5%), accuracy in the range 95–102%, high and consistent recovery and 
no matrix effect. The assay was linear across a range of 1–500 ng/ml, with a limit of 
quantitation of 2.5 ng/ml. Conclusion: We have developed and validated a method 
for analyzing pegcantratinib in human tumor biopsies, with the approach successfully 
applied to clinical trial samples.
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Published online: 23 January 2017
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Pegcantratinib is the first topically applied 
tropomyosin receptor kinase (TRK) inhibi-
tor that contains mini-PEGylated K252a, 
which exerts its effects at nanomolar concen-
trations by inhibiting the intracellular kinase 
domain of TRK [1]. Unlike other TRK inhib-
itors, which are available only in oral for-
mulations, the conjugation process of small 
molecules to PEG gives rise to physicochemi-
cal and pharmacological characteristics that 
optimize these molecules for topical routes of 
administration. This facilitates the delivery 
of high levels of the active ingredient to skin 
tumor cells, while avoiding the systemic side 
effects of oral applications [2].
Pegcantratinib has recently been evalu-
ated in a Phase llb clinical study setting as 
a potential treatment in common inflamma-
tory skin conditions, including psoriasis and 
atopic dermatitis, with a good safety profile 
observed [3]. The drug is now entering clini-
cal development in patients with germline 
mutations in the tumor suppressor gene 
CYLD, which include multiple clinical pre-
sentations of rare, skin appendage tumors: 
Brooke–Spiegler syndrome, familial cyl-
indromatosis and multiple familial tricho-
epitheliomas [4–6]. Patients carrying CYLD 
mutations face repeated disfiguring surgery 
to control tumor burden, with approximately 
one in four affected patients undergoing total 
scalp removal, due to the lack of an available 
pharmacological treatment [7]. Studies per-
formed in 3D primary cell cultures of cylin-
droma, treated with salicylic acid and TRK 
inhibitors, showed them to be particularly 
sensitive to K252a, with a surviving fraction 
of 50% (SF
50
) of 366 nM [8].
As part of an ongoing early phase clini-
cal trial, investigations of pegcantratinib 
tumor penetration and potential correlations 
between tumor exposure and response are 
warranted. Therefore, an analytical method 
was required to quantify pegcantratinib con-
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Figure 1. Chemical structures. Chemical structures and proposed surrogate ion structures of (A) Pegcantratinib 
and (B) CT340.
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centrations in tumor samples obtained from patients 
enrolled on the study. No published assay currently 
exists to measure pegcantratinib in tumor tissues, 
with LC–MS/MS method development for PEGylated 
drugs facing significant challenges due to the hetero-
geneity and relatively high MW of the PEG fraction. 
The mass spectrums generated show broad continuous 
peaks due to the size and charge distributions of PEG 
that are difficult to interpret and generally not usable 
for quantitative analysis [9]. However, recent papers 
have demonstrated that PEGylated therapeutic agents 
undergo collision-induced dissociation in the ioniza-
tion source (in-source CID) of the mass spectrometer, 
generating nonPEGylated precursor ions that can be 
used for drug quantification [10,11].
We have developed a sensitive and specific HPLC-
MS/MS assay, coupled with in-source CID, for direct 
quantitative measurement of pegcantratinib in human 
skin tumors. The method requires a small amount 
of tumor tissue, simple homogenization and extrac-
tion and short analysis time. After HPLC separation, 
the PEGylated small molecule undergoes in-source 
fragmentation in the instrument ionization source, 
generating a small molecule pegcantratinib-specific 
fragment ion that can be used as surrogate for the quan-
titative analysis. We validated the method according to 
the European Medicines Agency (EMA) guidance on 
bioanalytical method validation [12] and demonstrated 
its applicability to determine the drug’s tumor distri-
bution in skin tumor punch biopsies obtained from 
patients with CYLD mutations participating in the 
current Phase Ib/IIa clinical trial.
Experimental
Standards & chemicals
Analytical reference standards of pegcantratinib and 
CT340, used as internal standard (IS), were provided 
by Creabilis Therapeutics Srl (Colleretto Giacosa, 
Italy) and are shown in Figure 1. Analytical grade 
methanol, acetonitrile, DMSO and formic acid were 
purchased from Fisher Scientific (Leicester, UK).
Biological specimens
Human skin tumor biopsies were collected as routinely 
excised tumor from patients. These samples were snap 
frozen and stored at -80°C until analysis. Control 
tumor samples (no drug treatment) were used to pre-
pare the standards and quality control (QC) samples. 
Biopsies to be analyzed were excised at the end of treat-
ment, subdivided into three different layers (top, mid-
dle and bottom), snap frozen and stored at -80°C prior 
to analysis of pegcantratinib levels.
Standard & QC solutions
Stock solutions of pegcantratinib for standards and 
QCs were prepared in DMSO at a concentration of 
5 mg/ml. All stock solutions were diluted serially in 
methanol to generate working solutions with final 
pegcantratinib concentrations of 25, 50, 100, 500, 
1000 and 2500 ng/ml for standards, and 80, 800 and 
1600 ng/ml for working solutions of QCs. These work-
ing solutions were used to prepare the standard points 
of the calibration curve and the QC samples in homog-
enate control tissue, respectively. A stock solution of 
the IS (CT340) was prepared at 5 mg/ml in DMSO. 
The IS working solution was prepared at a concentra-
tion of 10 μg/ml by diluting the stock solution with 
methanol. All stock and working solutions were stored 
at -20 °C prior to use.
Tissue homogenate, standards & QC samples
Control tumor samples were weighed and homogenized 
using an Ultra Turrax homogenizer in 1% formic acid 
(1:5 ratio; w/v) and were used for preparation of cali-
bration curve and QC samples. Calibration curve stan-
dards were prepared by adding 10 μl of the working 
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Figure 2. In-source collision-induced dissociation/Q1 mass spectra of pegcantratinib. (A) at declustering potential 
20 V (B) at declustering potential 186 V and (C) MS/MS mass spectra of pegcantratinib.
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standard solutions to tumor homogenate (90 μl), to 
produce final concentrations of 2.5, 5.0, 10.0, 50.0, 
100 and 250 ng/ml. A blank sample (homogenate 
processed without IS), a zero blank sample (homog-
enate processed with IS) and three concentrations of 
QC samples in triplicate were included alongside the 
standard curve. QC samples were prepared by adding 
10 μl of working QC solutions to blank homogenate 
tumor (90 μl) to generate concentrations of 8.0, 80.0 
and 160 ng/ml.
Processing samples
Aliquots of homogenate (100 μl) from study samples, 
standards or QC samples were added with 10 μl 
(100 ng) of the IS working solution and 900 μl of 
acetonitrile and samples were vortex-mixed for 20 s. 
Following extraction, samples were centrifuged at 
4000 × g for 6 min at 4°C. The supernatants obtained 
were transferred to Eppendorf polypropylene tubes, 
evaporated to dryness under nitrogen at 37°C, and 
then reconstituted in 100 μl of mobile phase (MP) A 
and MP B in the proportion 1:1, v/v. MP A consisted 
of 1% formic acid in water and MP B was 1% formic 
acid in acetonitrile. After vortex mixing, samples were 
centrifuged at 4000 × g for 6 min at 4°C, supernatants 
were transferred to autosampler glass vials and 10 μl of 
each sample injected onto the HPLC–MS/MS system.
Chromatography conditions
The HPLC system consisted of a Series 200 autos-
ampler and micropump (Perkin Elmer, Beaconsfield, 
Bucks, UK). Samples were separated on a Kine-
tex C18 chromatographic column (2.6 μm, 50.0 
× 4.6 mm) coupled with a precolumn of the same 
material, both thermostatically controlled at 44°C. 
The HPLC system was set at a constant flow rate of 
0.5 ml/min and run under gradient conditions: step 
1 – 50% MP A for 1 min, step 2 – 50% MP A to 15% 
over 4 min; step 3 – constant 15% MP A for 2 min; 
step 4 – 15% MP A to initial conditions over 1 min; 
step 5 – reconditioning for 2 min.
MS conditions
Detection was obtained using an API 4000 triple 
quadrupole mass spectrometer SCIEX (CA, USA). 
Standard solutions (10 μg/ml) of pegcantratinib and 
IS were infused at a flow rate of 10 μl/min to optimize 
MS parameters, with mass spectra (MS1) and prod-
uct ion spectra (MS2) generated in positive ion mode. 
The HPLC–MS/MS system was equipped with a 
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Figure 3. Typical SRM chromatograms. (A) Extracted blank tumor sample, (B) extracted blank tumor sample with internal standard 
(zero sample), (C) extracted tumor sample with pegcantratinib at the LLOQ (2.5 ng/ml) and IS (D) extracted tumor biopsy sample from 
a patient treated with pegcantratinib with internal standard. Note different intensity scale in (A).
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Turbo Ion Spray source operated at 750°C and voltage 
of 5500 V. Clinical samples were analyzed with ESI, 
with zero air as nebulizer gas (60 psi) and heater gas 
(30 psi). Nitrogen was utilized as curtain gas (20 psi) 
and collision gas at 4 psi. The declustering potential 
(DP) was optimized and set to 186 V for in-source 
CID of both pegcantratinib and CT340. Quantifica-
tion was carried out in SRM mode with the follow-
ing transition: m/z 419.0→376.4 for both pegcantra-
tinib and IS, following chromatographic separation. 
Data were processed using the Analyst 1.6.2 software 
package (SCIEX).
Method validation
The method validation followed the EMA and the 
US FDA guidance on bioanalytical method valida-
tion [12,13]. The parameters validated were recovery, 
matrix effect, LLOQ, linearity and range, intra- and 
inter-day precision and accuracy, carryover effect and 
stability.
Recovery
The percentage extraction was determined in triplicate 
at three QC concentrations (8.0, 80.0 and 160 ng/ml) 
for pegcantratinib and at 1 μg/ml for the IS in tumor 
homogenate samples. Absolute recovery was deter-
mined by comparing the peak area of pegcantratinib 
extracted from homogenate tumor samples with the 
peak area in absence of matrix (true concentration of 
the analyte in solvent) that represents 100% recovery. 
The coefficient of variation (CV) was required to be 
within 15% [13].
Matrix effect
The matrix effect was assessed in four independent 
sources of blank matrix for pegcantratinib at the con-
centration of 100 ng/ml and IS at 10 μg/ml by calcu-
lating the matrix factor (MF) for each analyte, that is 
the ratio of the peak area of the analyte added to a pre-
extracted sample to the peak area of the same amount 
of analyte in solvent. The IS-normalized MF was cal-
culated by dividing the MF of the pegcantratinib by 
the MF of the IS. The CV of the IS-normalized MF 
should be within 15% [12].
Limit of quantification
The LLOQ of the method corresponded to the con-
centration of the lowest standard with precision ≤20% 
and accuracy within 80–120% of the nominal value, 
with a S/N ≥10. The LLOQ was assessed by preparing 
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five samples from a pool of tumor homogenate added 
with pegcantratinib at the defined concentration [12,13].
Linearity & range
The calibration curve linearity was validated over 
three working days, while the linear range was inves-
tigated by preparing samples <50% of the LLOQ 
and >150% of the ULOQ over one working day. 
For each standard concentration, the ratio of the 
HPLC-MS/MS peak area for pegcantratinib to IS was 
calculated and plotted against the nominal concentra-
tion of the drug in the sample. Linearity of the stan-
dard curves was assessed by regression analysis and the 
goodness of the fit calculated using Pearson’s determi-
nation coefficient, R2 and by comparing the true and 
back-calculated concentrations of the calibration stan-
dards. The accuracy of back-calculated values of an 
individual concentration were required to be within 
85–115% of the theoretical concentration (80–120% 
at the LLOQ), and all standards had to meet these 
criteria [12,13].
Intra-/interassay precision & accuracy
Five replicates per QC concentration were analyzed for 
intraday precision and accuracy, while interday preci-
sion and accuracy were determined from three separate 
experiments carried out on different days. The preci-
sion of the method at each concentration was reported 
as the CV value, expressing the SD as a percentage 
of the mean calculated concentration; accuracy was 
determined by expressing the mean calculated con-
centration as a percentage of the nominal concentra-
tion. In each run, the concentration measured for QC 
samples was required to be within 15% of the nominal 
value [12,13].
Carryover
Carryover of pegcantratinib and IS were evaluated by 
placing a blank sample, without analyte or IS, imme-
diately after the highest calibration standard. Response 
for analyte in the carryover sample was required to be 
≤20% of the response at LLOQ. The response for IS 
in the carryover sample was required to be ≤5% of the 
response for the control matrix + IS [12,13].
Stability
The stability of pegcantratinib in homogenate tumor 
was assessed by analyzing QC samples (low and high 
concentrations) in triplicate following storage and han-
dling. Short-term stability was assessed in QC samples 
unextracted and extracted (autosampler stability) from 
the tumor matrix after 10 days stored at 4°C, the 
bench-top stability was determined after 4 h at room 
temperature. Freeze–thaw stability was assessed for 
three freeze–thaw cycles. We also analyzed the sta-
bility of blank frozen homogenate tumor (stored at 
-20°C), which was used to prepare QCs on the day of 
the analysis. Long-term stability was assessed in QC 
Table 1. Recovery of pegcantratinib from human tumor homogenate at quality control 
concentrations (n = 5).
Pegcantratinib concentration (ng/ml) Recovery (%) ± SD CV (%)
8.00 89.7 ± 11.9 13.2
80.0 93.7 ± 8.94 9.54
160 86.4 ± 10.4 12.0
Internal standard 84.9 ± 1.61 1.90
CV: Coefficient of variation.   
Table 2. Matrix effect of four different types of human tissue homogenate on pegcantratinib 
(100 ng/ml) and internal standard (1μg/ml).
Tissue type Pegcantratinib (MF) CT340 (MF) Ratio
Skin with anagen follicles 1.05 1.05 1.00
Cylindroma and spiradenoma 0.97 0.96 1.01
Cylindroma only 1.07 1.05 1.02
Spiradenoma only: 0.92 1.01 0.91
– Mean 1.00 1.02 0.99
– SD 0.07 0.04 0.05
– CV (%) 7.1 3.9 5.0
CV: Coefficient of variation; MF: Matrix factor.
284 Bioanalysis (2017) 9(3)
Figure 4. Calibration curve showing linearity over six concentrations of pegcantratinib (range: 2.5–250 ng/ml) 
from three separate experiments.
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samples stored at -20°C for 3 months. The pegcantra-
tinib QC samples were analyzed against a calibration 
curve, obtained from freshly spiked calibration stan-
dards, and the obtained concentrations were compared 
with the nominal concentrations. The mean concen-
tration at QC concentration was required to be within 
±15% of the nominal concentration [12,13].
Analysis of clinical samples
Biopsies weighing 5–20mg were obtained from cyl-
indroma skin tumors of two CYLD carrier patients 
enrolled in a Phase Ib open label clinical trial 
(ISRCTN: 75715723) that received daily topical doses 
of pegcantratinib (0.5% w/w) for 4 weeks. Biopsies 
were excised at the end of treatment as described above.
Results
Optimization of HPLC–MS/MS parameters 
& conditions
Using an ESI source in positive ion mode coupled with 
in-source CID, pegcantratinib and IS generated an 
abundant fragment ion after applying an optimized DP. 
As seen previously, the mass spectrum of pegcantratinib 
at a nondissociating voltage of 20 V (Figure 2A) com-
pared with a high DP of 186 V (Figure 2B), showed the 
disappearance of the characteristic broad profile associ-
ated with PEGylated molecules. This indicates that the 
polymeric species was dissociated and an abundant new 
ion species at m/z 419.0 was generated (Figure 1). The 
PEG disassociation was obtained for both the analyte 
and the IS. The newly obtained ion (m/z 419.0) passed 
Table 3. LLOQ of pegcantratinib in human tumor homogenate.
Actual concentration (ng/ml) Found concentration (ng/ml) Accuracy (%)
2.5 2.22 89
– 2.57 103
– 2.58 103
– 2.41 96
– 2.59 104
Mean (n = 6) 2.47 –
SD 0.16 –
Accuracy (%) 99 –
Precision (%) 6.0 –
www.future-science.com 285future science group
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through the first quadrupole into the collision cell where 
the collision energy was optimized to obtain product 
ions with a high signal (Figure 2C). The characteristic 
product ions were monitored in the third quadrupole 
at m/z 376.4 (34 eV) and 348.3 (41 eV). Pegcantra-
tinib and IS were quantified using the transitions m/z 
419.0→376.4 and were distinguished by their different 
retention times of approximately 2.7 and 2.1 min for 
pegcantratinib and IS, respectively. Elution of the ana-
lytes was rapid and selective. No interfering peaks were 
present at these retention times, and the peaks were 
completely resolved from the tumor matrix. Figure 3 
presents typical SRM chromatograms: Figure 3A is an 
extracted blank tumor sample; Figure 3B is an extracted 
blank tumor sample with IS; Figure 3C is an extracted 
tumor sample at the LLOQ (2.5 ng/ml) with IS added; 
and Figure 3D represents an extracted tumor sample 
from a patient treated with pegcantratinib.
Recovery
Recovery was evaluated in triplicate over the three QC 
concentrations by comparing the peak areas of spiked 
homogenate tumor samples, following extraction, with 
those obtained from direct injection of pegcantratinib 
standard solutions in MP. The recovery percentage was 
>86% for pegcantratinib and 85% for IS. There were no 
significant variations in CV (<13%) as shown in Table 1.
Matrix effect
Due to difficulty in obtaining different types of human 
tumor, the matrix effect was evaluated during the pre-
validation study, when four different types of matrix 
were available.
No matrix effect was observed in four independent 
matrix sources including three different tumors and 
normal skin, evaluated by assessment of IS-corrected 
MF, with a mean ratio of 0.99 ± 0.05 and CV of 5% 
observed (Table 2).
Limit of quantification
The LLOQ concentration in tumor homogenate was 
defined to be 2.5 ng/ml, with precision and accuracy 
of 6 and 99%, respectively. Single values are shown in 
Table 3.
Table 4. Interday linearity, accuracy and precision of calibration curves of pegcantratinib in human 
tumor homogenate.
Day Pegcantratinib concentration (ng/ml)
1.00 2.50 5.00 10.0 50.0 100 250 500
1 0.97 2.63 4.82 9.22 50.3 104 261 481
2 NA 2.59 4.95 9.11 57.0 92.8 267 NA
3 NA 2.46 5.02 10.5 50.3 97.1 247 NA
Mean (n = 4) NA 2.56 4.93 9.61 52.5 98.0 258 NA
SD NA 0.09 0.10 0.77 3.87 5.65 10.3 NA
Accuracy (%) 97 102 99 96 105 98 103 96
Precision (%) NA 3 2 8 7 6 4 NA
NA: Not applicable.
Table 5. Intraday precision and accuracy of the method for the analysis of pegcantratinib in human 
tumor homogenate.
 
 
Nominal concentration (ng/ml)
8.00 80.0 160
Measured concentration 8.47 72.7 154
 7.52 69.6 151
 7.18 82.1 160
 7.27 81.9 163
 8.14 75.4 164
Mean (n = 5) 7.72 76.3 158
SD 0.56 5.56 5.68
Accuracy (%) 96.5 95.4 99.0
Precision (%) 7.3 7.3 3.6
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Linearity & range
Examination of linearity over six concentrations of 
pegcantratinib (range: 2.5–250 ng/ml) yielded a lin-
ear correlation of ≥0.995 from three separate experi-
ments (Figure 4). The range of the method was exam-
ined between 1.0 and 500 ng/ml over one working 
day. Results are shown in Table 4.
Intra-/interassay precision & accuracy
Intra-assay experiments showed precision rang-
ing from 3.6 to 7.3% and accuracy of 95.4–99.0% 
(n = 5). Interassay experiments carried out over three 
days showed precision ranging from 4.67 to 8.50% 
and accuracy of 96.1–99.4% (n = 11) (Tables 5 & 6).
Carryover & stability
No carryover was detected for pegcantratinib or IS 
in chromatograms of blank samples injected imme-
diately following ULOQ samples. The stability of 
pegcantratinib in homogenate tumor was assessed by 
analyzing QC samples (low and high) in triplicate. 
Pegcantratinib was stable in tumor for at least 4 h 
at room temperature and for 10 days at 4°C before 
and after extraction. Control tumor homogenate, 
stored at -20°C was shown to be stable for prepara-
tion of standards and QCs. Pegcantratinib was stable 
in tumor homogenate at -20°C over 3 freeze–thaw 
cycles.
Clinical trial tumor distribution
The present method was applied to the quantita-
tive analysis of pegcantratinib in human skin tumor 
biopsies obtained following 4 weeks of daily topical 
pegcantratinib treatment, from two CYLD carrier 
patients enrolled in a Phase lb open label clinical trial. 
The punch biopsies obtained were sliced in three dif-
ferent layers to determine drug penetration. Results 
presented in Table 7 show a clear trend toward higher 
drug concentration in the top layers, with drug also 
able to penetrate to the inner layers.
Discussion
The TRK inhibitor, pegcantratinib, currently being 
investigated in early phase clinical trials for the 
Table 6. Interday precision and accuracy of the method for the analysis of pegcantratinib in human 
tumor homogenate.
Nominal concentration (ng/ml)
8.00 80.0 160
Measured concentration 8.47 72.7 154
 7.52 69.6 151
Day 1 7.18 82.1 160
 7.27 81.9 163
 8.14 75.4 164
Day 2 9.02 78.2 138
 8.49 77.5 150
 8.85 76.7 154
Day 3 7.88 78.2 162
 7.21 76.5 171
 7.47 77.0 177
Mean (n = 11) 7.95 76.9 159
SD 0.68 3.59 10.74
Accuracy (%) 99.4 96.1 99.1
Precision (%) 8.50 4.67 6.77
Table 7. Pegcantratinib tumor concentrations obtained in three tumor layer levels from two CYLD 
mutation carrier patients treated in a Phase Ib trial.
Patient number Tumor concentration (ng/ml)
Top layer Middle layer Bottom layer
1 321 41.1 11.0
2 279 19.5 16.2
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treatment of patients with germline mutations in the 
tumor suppressor gene CYLD, provides several chal-
lenges in terms of development of an analytical assay 
for drug quantification. No assay has been published 
for this mini-PEGylated agent, with assay develop-
ment for PEGylated drugs historically facing signifi-
cant hurdles due to the heterogeneity and high MW 
of the PEG fraction [9]. In addition, as pegcantratinib 
is being developed in this clinical situation for topi-
cal administration, an assay was required to allow 
the quantitation of drug levels extracted from tumor 
material collected by punch biopsies.
We have developed a sensitive and specific HPLC–
MS/MS assay, coupled with in-source CID, for 
direct quantitative measurement of pegcantratinib 
in human skin tumors. The novel method involves 
HPLC separation of the PEGylated small molecule, 
followed by in-source fragmentation in the instru-
ment ionization source, generating a small molecule 
pegcantratinib-specific fragment ion that can be used 
as surrogate for the quantitative analysis. Excellent 
sensitivity was achieved, with an LLOQ below values 
previously published for PEGylated molecules [10,11]. 
We have successfully validated the method according 
to the EMA guidance on bioanalytical method vali-
dation [12] and demonstrated its applicability to deter-
mine the drug’s tumor distribution in skin tumor 
punch biopsies obtained from patients with CYLD 
mutations participating in the current clinical trial.
Conclusion & future perspective
The bioanalytical method described, based on simple 
tumor homogenization and acetonitrile extraction 
followed by HPLC–MS/MS coupled with in-source 
CID analysis, was validated for the quantitative mea-
surement of the PEGylated molecule, pegcantratinib, 
in human tumor biopsies. The method requires small 
amounts of tumor matrix; it is selective, sensitive, 
precise and accurate. It was successfully employed 
to measure concentrations of pegcantratinib in 
human skin tumor biopsies of CYLD carrier patients 
enrolled in a Phase Ib open label clinical trial. The 
preliminary clinical data obtained showed tumor 
drug absorption and penetration to inner tumor 
layers. Data concerning the tumor exposition will 
provide useful information for investigating corre-
lations between tumor exposure and response in an 
expanded Phase Ib/IIa clinical trial.
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Executive summary
Background
•	 An LC method coupled with in-source collision-induced dissociation MS was developed and validated to 
quantify pegcantratinib in skin tumor biopsies of patients enrolled in an early phase clinical to determine 
tumor penetration.
Experimental
•	 The sample preparation procedure required a 10 mg sample for tissue homogenization and involved protein 
precipitation with acetonitrile following addition of internal standard.
Results & discussion
•	 The method is selective, precise, accurate and sensitive, with an LLOQ of 2.5 ng/ml in tumor.
•	 The preliminary clinical data showed tumor drug absorption and penetration to inner tumor layers.
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